Cite
HARVARD Citation
Isa, F. et al. (2022). Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19. International journal of infectious diseases. pp. 585-592. [Online].